Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2015 Fourth Quarter And Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sanofi Collaboration Drives Lexicon Pharma's (LXRX) 4Q Success; Wedbush Raises Price Target to $28
March 2, 2016 7:30 AM ESTWedbush reiterated an Outperform rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), and raised the price target to $28.00 (from $26.00), following the company's 4Q earnings report. Revenues of $127.2MM came in above consensus estimates of $0.3MM. The beat comes due to revenues recognized from the collaboration agreement with... More
Lexicon Pharma (LXRX) Reports Q4 EPS of $0.76
March 1, 2016 7:11 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.76, versus ($0.03) reported last year. Revenue for the quarter came in at $127.3 million, versus $21.5 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... More